Commenting on three potential measures for the prospective payment system-exempt cancer hospital quality reporting program, AHA July 19 urged the Centers for Medicare & Medicaid Services (CMS) and measure developers to fully field test each of the measures in dedicated cancer hospitals. “All three measures assess important aspects of cancer care, and the AHA supports their continued development,” wrote AHA Executive Vice President Rick Pollack. “However, we strongly urge the measure developers and CMS to fully utilize field testing in dedicated cancer hospitals to ensure each measure is sufficiently rigorous for a public reporting program and can be feasibly collected without undue burden. We also strongly urge CMS to obtain endorsement of the measures from the National Quality Forum, as well as prerulemaking review by the Measure Applications Partnership before formally proposing any of the measures” for the quality reporting program. The potential measures are: initiation of osteoclast inhibitors for patients with multiple myeloma or bone metastases associated with breast cancer, prostate cancer or lung cancer; overuse of imaging for staging breast cancer at low risk of metastasis; and potentially avoidable admissions and emergency department visits among patients receiving outpatient chemotherapy. For more on the letter, click on: http://tinyurl.com/l3shayx.